神经分泌生物科学 NBIX 深 沪
等待开盘 07-01 09:30:00 美东时间
168.535
-1.465
-0.86%
华盛通- 最 高171.50
- 今 开170.66
- 成交量 107.58万股
- 最 低 168.24
- 昨 收 170.00
- 总市值 169.46亿
- 52周最高 171.50
- 市盈率 静 36.09
- 换手率 1.07%
- 52周最低 122.1375
- 委 比 -49.02%
- 总股本 1.01亿
- 历史最高 171.50
- 量 比 0.82
- 振 幅 1.92%
- 历史最低 5.42
- 每 手 1
- 风险率 10.68%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多瑞银称Neurocrine Biosciences的Ingrezza增长势头有望支撑2026年业绩指引上调
瑞银发布针对神经内分泌生物科学公司（NBIX）的研报，维持其买入评级，将目标价从182美元上调至208美元。 核心调整与预期数据： 将药物Ingrezza的...
今天 04:31
今日牛股：Neurocrine Biosciences（NBIX）
Neurocrine Biosciences（股票代码：NBIX）凭借旗舰药物INGREZZA热销、扩容的商业化产品组合及后期研发管线，成为可创造现金流的盈利型...
06-29 17:05
Neurocrine Biosciences' Soleno Therapeutics Announces Late-Breaking Data At ENDO 2026 Showing Two Years Of VYKAT XR After 16‑Week Withdrawal Sustained Improvements In Hyperphagia And Behavioral Symptoms In PWS
Participants who resumed VYKAT XR following a 16-week randomized withdrawal period demonstrated improvements in hyperphagia and behavioral symptoms as early as Week 13, with benefits continuing through 2 years VYKAT XR demonstrated statistically significant and sustained improvements in hyperphagia ...
06-16 04:15
Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference
Voyager Therapeutics CEO Alfred W. Sandrock Jr., M.D., Ph.D., will participate in a pre-recorded fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference. The webcast will be available on June 15, 2026, at 7:00 a.m. ET on the Company’s investor website and archived for 30 days. Voyager Therapeutics focuses on using human genetics to treat neurological diseases, with programs targeting Alzheimer’s, Parkinson’s, ALS, and...
06-11 20:01
Neurocrine Biosciences Reports New Clinician-Reported Data In Participants With Intellectual, Developmental Disabilities At American Academy Of Developmental Medicine And Dentistry's Education Conference
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new clinician-reported data in patients with intellectual and developmental disabilities demonstrating meaningful and rapid improvements in tardive
06-08 20:38
Neurocrine Biosciences将在2026年内分泌学会年会上公布关键临床及患者报告结局指标的克立色芬两年期CRENESSITY新数据
Neurocrine生物科学公司（纳斯达克股票代码：NBIX）宣布将在6月13 - 16日于芝加哥举行的内分泌学会年度会议ENDO 2026上，公布使用CRE...
06-03 20:34
美股大行评级 | 潜在涨幅43%，慧与获11家大行集体上调目标价；最高300美元，Credo获9家大行集体上调目标价
今日重点评级关注：Ascendiant Capital：维持Genasys"买入"评级，目标价从5.5美元升至6美元；Citizens：维持Abivax"跑赢大市"评级，目标价从131美元升至187美元
06-03 11:17
Neurocrine Biosciences15分钟走势图显示，MACD死叉、KDJ死叉预示看跌趋势
2026年6月1日11点，Neurocrine Biosciences公司15分钟走势图出现MACD死叉和KDJ死叉。 技术指标显示股价将继续下行，下跌动能或增...
06-01 23:18
美股大行评级 | Susquehanna上调美光目标价从600美元升至1750美元；戴尔、MongoDB、网泰信息存储、Nextpower、Okta等获多家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持Aclarion"买入"评级，目标价从7美元升至7.5美元；Susquehanna：维持美光科技"积极"评级，目标价从600美元升至1750美元
06-01 14:11
RBC Capital Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $183
RBC Capital analyst Brian Abrahams maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Outperform and raises the price target from $180 to $183.
05-30 00:30
